Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximabShort Communication Published on 2023-07-282024-09-04 Journal: Journal of clinical and experimental hematopathology : JCEH [Category] 대상포진, [키워드] Bendamustine diffuse large B-cell lymphoma MYC translocation polatuzumab vedotin [DOI] 10.3960/jslrt.23017 PMC 바로가기 [Article Type] Short Communication